Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Ian D DavisAndrew J MartinMartin R StocklerStephen BegbieKim N ChiSimon ChowdhuryXanthi CoskinasMark FrydenbergWendy E HagueLisa G HorvathAnthony M JoshuaNicola J LawrenceGavin MarxJohn McCaffreyRay McDermottMargaret McJannettScott A NorthFrancis ParnisWendy ParulekarDavid W PookM Neil ReaumeShahneen K SandhuAlvin TanT Hsiang TanAlastair ThomsonEmily TuFrancisco Vera-BadilloScott G WilliamsSonia YipAlison Y ZhangRobert R ZielinskiChristopher J Sweeneynull nullPublished in: The New England journal of medicine (2019)
Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetaxel. (Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; ClinicalTrials.gov number, NCT02446405; and EU Clinical Trials Register number, 2014-003190-42.).